Market News

Altimmune, Inc. (ALT) Analysts See $-0.50 EPS; Evanson Asset Management Increased Facebook (FB) Stake By $7.93 Million

Analysts expect Altimmune, Inc. (NASDAQ:ALT) to report $-0.50 EPS on March, 13.They anticipate $12.30 EPS change or 104.24% from last quarter’s $11.8 EPS. After having $-0.34 EPS previously, Altimmune, Inc.’s analysts see 47.06% EPS growth. The stock increased 1.96% or $0.03 during the last trading session, reaching $1.56. About 292,219 shares traded or 25.84% up from the average. Altimmune, Inc. (NASDAQ:ALT) has 0.00% since February 11, 2017 and is . It has underperformed by 16.70% the S&P500.

Evanson Asset Management Llc increased Facebook Inc (FB) stake by 10.95% reported in 2017Q3 SEC filing. Evanson Asset Management Llc acquired 46,669 shares as Facebook Inc (FB)’s stock rose 10.88%. The Evanson Asset Management Llc holds 472,722 shares with $80.77M value, up from 426,053 last quarter. Facebook Inc now has $511.60 billion valuation. The stock increased 2.64% or $4.53 during the last trading session, reaching $176.11. About 39.89M shares traded or 92.10% up from the average. Facebook, Inc. (NASDAQ:FB) has risen 26.75% since February 11, 2017 and is uptrending. It has outperformed by 10.05% the S&P500.

Altimmune, Inc., a clinical stage immunotherapeutic biotechnology company, creates and develops immunotherapeutic products for treating acute respiratory infections, chronic viral infections, and cancer. The company has market cap of $24.38 million. The firm develops NasoVAX, an intranasally administered recombinant influenza vaccine that has completed Phase I clinical trials; and HepTcell, an immunotherapy for patients chronically infected with the hepatitis B virus, which is in Phase I clinical trials. It currently has negative earnings. The Company’s preclinical stage products include NasoShield, a vaccine for the prevention of anthrax disease following inhalation of pathogen spores; and Oncosyn, an immunotherapeutic for treating solid cancer indications, such as lung, colorectal, melanoma, breast, ovarian, and others.

Among 54 analysts covering Facebook (NASDAQ:FB), 50 have Buy rating, 2 Sell and 2 Hold. Therefore 93% are positive. Facebook had 236 analyst reports since July 21, 2015 according to SRatingsIntel. Susquehanna initiated the stock with “Positive” rating in Monday, August 10 report. The firm has “Buy” rating given on Friday, May 13 by M Partners. RBC Capital Markets maintained Facebook, Inc. (NASDAQ:FB) rating on Wednesday, June 7. RBC Capital Markets has “Buy” rating and $18500 target. Robert W. Baird maintained Facebook, Inc. (NASDAQ:FB) rating on Tuesday, January 16. Robert W. Baird has “Buy” rating and $200.0 target. BMO Capital Markets maintained the shares of FB in report on Thursday, July 13 with “Hold” rating. The stock of Facebook, Inc. (NASDAQ:FB) has “Strong Buy” rating given on Thursday, July 27 by Raymond James. The stock has “Buy” rating by Canaccord Genuity on Thursday, July 30. Cantor Fitzgerald maintained Facebook, Inc. (NASDAQ:FB) rating on Friday, July 21. Cantor Fitzgerald has “Buy” rating and $18000 target. Pivotal Research maintained Facebook, Inc. (NASDAQ:FB) rating on Thursday, November 5. Pivotal Research has “Buy” rating and $134 target. The company was maintained on Thursday, August 27 by Cantor Fitzgerald.

Leave a Reply

Your email address will not be published. Required fields are marked *